Acer Therapeutics' Series B Round

Acer Therapeutics raised a round of funding on May 06, 2016.

Acer Therapeutics is developing the first pharmaceutical therapy for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism.…

Articles about Acer Therapeutics' Series B Round: